Study: Could Psilocybin-Assisted Therapy Help Fibromyalgia

• By Healing Maps Editorial Staff
• February 28, 2025February 28, 2025
• mental health Psilocybin Articles psilocybin mushrooms psychedelics
• With 0 comments

Fibromyalgia, a chronic condition marked by widespread pain, fatigue, and cognitive disturbances, affects millions worldwide. Traditional treatments often fall short, prompting researchers to seek alternative therapies. A recent pilot study investigates the potential of psilocybin-assisted therapy (PAT) for individuals with fibromyalgia.

New: Interested in Being Part of a Psychedelics-Focused Clinical Trial? Sign Up Here

Study Overview

Conducted by the University of Michigan, this open-label trial involved five participants diagnosed with fibromyalgia. Each received two doses of oral psilocybin (15 mg and 25 mg) two weeks apart, alongside psychotherapy sessions. The primary aim was to assess safety, while secondary objectives focused on evaluating pain severity, interference, and sleep disturbances.

Safety Findings

Participants experienced transient increases in blood pressure and heart rate during dosing, which normalized by the end of treatment. No serious adverse events were reported. Four participants noted brief headaches following dosing.

Effectiveness Outcomes

One month post-treatment, participants reported significant improvements:

• Pain Severity: Decreased by 2.1 points on a 10-point scale.
• Pain Interference: Reduced by 1.8 points.
• Sleep Disturbance: Improved by 2.5 points.

These changes suggest that PAT may offer meaningful relief for fibromyalgia symptoms.

Participant Feedback

Using the Patient Global Impression of Change scale, one participant reported their symptoms as “very much improved,” two as “much improved,” and two as “minimally improved.”

Implications and Future Research

While this pilot study provides promising insights, its small sample size and open-label design limit generalizability. The researchers advocate for larger, randomized controlled trials to further evaluate the efficacy and safety of PAT for fibromyalgia.

This study contributes to the growing body of research exploring psychedelic-assisted therapies for chronic pain conditions. If subsequent trials confirm these findings, PAT could become a valuable addition to fibromyalgia treatment options.

For more detailed information, refer to the full study published in Frontiers in Pain Research.